Technical Analysis for RARE - Ultragenyx Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade D 57.18 0.97% 0.55
RARE closed up 0.97 percent on Friday, May 24, 2019, on 58 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical RARE trend table...

Date Alert Name Type % Chg
Jack-in-the-Box Bearish Bearish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup 0.97%
Lower Bollinger Band Walk Weakness 0.97%
Multiple of Ten Bearish Other 0.97%
Below Lower BB Weakness 0.97%
Lower Bollinger Band Touch Weakness 0.97%
Oversold Stochastic Weakness 0.97%
Slingshot Bearish Bearish Swing Setup -2.37%

Older signals for RARE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Ultragenyx Pharmaceutical Inc., a development-stage biotechnology company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare diseases in the United States. It develops various biologics product candidates, including KRN23, a human monoclonal antibody to bind and reduce the biological activity of fibroblast growth factor to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia; recombinant human beta-glucuronidase, an intravenous enzyme replacement therapy for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A, an enzyme replacement therapy for galactosialidosis. The company is also developing a range of small-molecule product candidates comprising triheptanoin, a substrate replacement therapy for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and oral formulation of sialic acid to treat hereditary inclusion body myopathy. It has license agreements with AAI Pharma Services Corp. and HIBM Research Group; and a collaboration and license agreement with Nobelpharma Co., Ltd. The company was founded in 2010 and is headquartered in Novato, California.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Pharmacy Rare Diseases Enzyme Replacement Therapy Biologics Rare And Ultra Rare Diseases
Is RARE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 90.98
52 Week Low 37.44
Average Volume 518,065
200-Day Moving Average 62.704
50-Day Moving Average 66.6116
20-Day Moving Average 62.6165
10-Day Moving Average 60.174
Average True Range 2.8087
ADX 38.17
+DI 8.1581
-DI 29.2926
Chandelier Exit (Long, 3 ATRs ) 60.4839
Chandelier Exit (Short, 3 ATRs ) 64.3261
Upper Bollinger Band 69.1187
Lower Bollinger Band 56.1143
Percent B (%b) 0.08
BandWidth 20.768328
MACD Line -2.4575
MACD Signal Line -1.8594
MACD Histogram -0.5981
Fundamentals Value
Market Cap 2.43 Billion
Num Shares 42.6 Million
EPS -6.74
Price-to-Earnings (P/E) Ratio -8.48
Price-to-Sales 16800.34
Price-to-Book 4.53
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.96
Resistance 3 (R3) 60.14 59.39 59.49
Resistance 2 (R2) 59.39 58.69 59.30 59.34
Resistance 1 (R1) 58.29 58.25 58.84 58.11 59.18
Pivot Point 57.54 57.54 57.82 57.45 57.54
Support 1 (S1) 56.44 56.84 56.99 56.26 55.18
Support 2 (S2) 55.69 56.40 55.60 55.02
Support 3 (S3) 54.59 55.69 54.87
Support 4 (S4) 54.41